Stock 1877 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Market Closed - Hong Kong S.E.
Other stock markets
 03:59:36 2024-06-27 EDT 		5-day change 1st Jan Change
11.68 HKD -2.67% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. +1.57% -39.92%
06-26 Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8% MT
06-25 Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shanghai Junshi Biosciences Breast Cancer Drug Obtains DRC from NMPA; Shares Jump 8%
MT
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration
CI
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
CI
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator
MT
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration
CI
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
MT
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
MT
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
CI
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection
MT
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
CI
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection
CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.
CI
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates
MT
Junshi Bio's 2023 Loss Widens, Misses Estimates
MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Junshi Biosciences Proposes Share Buyback
MT
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA
MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. News Shanghai Junshi Biosciences Co., Ltd.
  5. Highlights